trending Market Intelligence /marketintelligence/en/news-insights/trending/r743iwobn5xwja62qguega2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Merck's Ebola vaccine found effective; Teva settles corruption probe

Street Talk Episode 41 - How to Win the Funding Battle, Use Fintech to Play Offense

Forward Spark Spreads Suggest Rising Profitability Of US Renewables As Sector Matures

MA Activity The Big Story In Mature Online Video Platform Market

Martina Cheung Backs The Quality Program

Merck's Ebola vaccine found effective; Teva settles corruption probe

* Merck & Co. Inc.'s rVSV-ZEBOV experimental vaccine was successful in preventing Ebola infection in humans, according to a study published in The Lancet. The trial, led by the World Health Organization and Guinea's Ministry of Health among other partners, recorded no cases of Ebola after a 10-day incubation period in its final stage.

* Teva Pharmaceutical Industries Ltd. agreed to pay $519 million to the U.S. Department of Justice and the SEC in a settlement of charges to bribe government officials in Ukraine, Mexico and Russia. The company admitted that its executives and employees bribed a high-ranking Russian government official to boost sales of its multiple sclerosis drug, Copaxone, during annual drug purchase auctions held by the country's Ministry of Health.

* According to The Wall Street Journal, President-elect Donald Trump's pick for the Health and Human Services Department traded stocks in almost 40 healthcare-related companies while in office, including Pfizer Inc., Amgen Inc. and Bristol-Myers Squibb Co. Tom Price, R-Ga., also sponsored nine and co-sponsored 35 healthcare-related bills in the House that may have affected the companies' stock prices, the publication said.

M&A and capital markets

* Pfizer acquired AstraZeneca PLC's late-stage small molecule anti-infective business for an upfront payment of $550 million and a further $175 million in January 2019. Pfizer gained commercialization and development rights to the unit's products which are primarily outside the U.S. and is required to make $250 million in commercial, manufacturing and regulatory milestones.

* PerkinElmer Inc. plans to sell its medical imaging business to Varian Medical Systems Inc. The deal is expected to close in the first half of 2017.

* Prestige Brands Holdings Inc. agreed to acquire fellow competitor C.B. Fleet Co. for $825 million cash. The move will help bolster Prestige's women's health, gastrointestinal and pediatric care portfolio, and is expected to add approximately $1 billion in pro forma revenues in fiscal 2018.

* Japan's Sumitomo Dainippon Pharma Co. Ltd. said it will acquire U.S. biotech startup Tolero Pharmaceuticals Inc. for $220 million in upfront and other milestone payments. Tolero Pharmaceuticals specializes in therapeutic agents in oncology and hematological disorders.

Drug and product pipeline

* Japan's Health Ministry began drafting guidelines for physicians to reduce antibiotic use to two-thirds of the current level in Japan, according to PharmaJapan. The manual is part of a global effort urged by the World Health Organization to combat antibiotic-resistant bacteria.

* Synergy Pharmaceuticals Inc.'s Plecanatide showed superiority compared to placebo in its second phase 3 trial involving adult patients with irritable bowel syndrome with constipation. The drug is being reviewed for the treatment of chronic idiopathic constipation by the U.S. FDA.

Operational activity

* Ligand Pharmaceuticals signed a global license and supply agreement with Novartis AG for development and commercialization of a Captisol-enabled liquid formulation of trametinib, a cancer drug. Captisol optimizes the solubility and stability of drugs.

* Meanwhile, Ono Pharmaceutical Co. Ltd. secured a global license for Ligand Pharmaceuticals' OmniAb platform to discover antibody-based treatments for diseases.

* In other news, Poxel SA CFO Eric Massou resigned to pursue other professional opportunities. Massou's replacement will be announced in the first quarter of 2017.

* Horizon Pharma PLC secured preliminary approval for a U.S. patent that would cover its Ravicti oral treatment for urea cycle disorders in patients older than two years of age.

The day ahead

Early morning futures indicators pointed to a lower opening for the U.S. market.

In Asia, the Hang Seng fell 0.28% to 21,574.76.

In Europe as of midday, the FTSE 100 was up 2.01% to 7,065.69 while the Euronext 100 increased by 0.06% to 929.40.

The Daily Dose is updated as of 6:30 a.m. ET. Some external links may require a subscription.